|
|
 |
|
Viewing report
|
|
|
|
Prostate and Breast Cancer- New Treatments & Developmental Progress
Bioseeker, March 2007, Pages: 192
Introduction
The treatment for breast and prostate cancer are under intense progress. Cancer of the prostate is the second most frequently diagnosed cancer in men in the US and approximately 3 million women in the US are living with breast cancer. Several new approvals have changed the landscape of options for the treatment of late stage breast and prostate cancer. Newly approved drugs are showing increased sale figures, and several of them are reaching for broader indications. So, the trend of continuously increasing revenues is expected for drugs presenting reliable clinical data to support their successful progress.
Research and analysis highlights
In the report 'Prostate & Breast Cancer - New Treatments & Developmental Progress' BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate and breast cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified approximately 200 drug candidates in clinical stage of development and more than 125 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in these markets and current treatments will be changed for the benefit of more innovative therapies.
Scope of this report
-Thorough examination of status and impact of several novel drugs in development
-Discussion of the challenges in current and future treatment strategies
-Anticancer pipeline of most companies in the field
Key reasons to read this report
-Explore the strengths and weaknesses associated with compounds in clinical development.
-Scientific rationale for most novel therapeutics in breast and prostate cancer R&D, and the results of clinical trials to date
-Gain insight into the current challenges and commercial opportunities associated with breast and prostate cancer therapy
-Two hundred high quality references
Some of the drugs included in this analysis:
4HPR, Anastrozole, Arsenic trioxide, Arzoxifene, Bevacizumab, Bortezomib, BMS-247550, DCVax-prostate, Doxorubicin, Epothilone D, Erlotinib, Exemestane, Exisulind, Fulvestrant, Gefitinib, Goserelin, GVAX, Imatinib, ixabepilone, KOS-862, Lapatinib, Letrozole, Lonafarnib, NX473, Oblimersen sodium, Patupilone, Pemetrexed, PTK/ZK, R-flurbiprofen, Toremifene Temsirolimus, Theratope, Tipifarnib, Trastuzumab, Satraplatin, SDX-105, sipuleucel-T, Sorafenib tosylate, Vapreotide
Customers who bought this item also bought
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Prostate Cancer - A Therapeutic & Competitive Insight
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Breast Cancer - Therapeutic And Competitive Insights
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
Triple Analysis: Decoding Big Pharma's R&D Strategy In Oncology and Special Focus on Breast and Prostate Cancer
Analytical Tool - Prostate Cancer
Analytical Tool - Prostate Cancer: A Therapeutic & Competitive Insight
U.S. Breast Cancer Therapeutics Markets
Analytical Tool - Breast Cancer
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Analytical Tool - Breast Cancer Therapeutics & Competitive Insights
|
|
|
|
